June 2026 – OncLive

Atebimetinib Plus Modified Gemcitabine/Nab-Paclitaxel Shows Encouraging Efficacy, Tolerability in First-Line Metastatic PDAC

immuneering-logo-no-shadow
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.